CUE-221 Shows Dose-Consistent Activity in Chinese Urticaria Study
Cue Biopharma disclosed positive topline results from a 145-participant randomized double-blind Phase 2 study of CUE-221, also called UB-221, conducted in China by Genesis Life Sciences. Complete weekly hive score resolution at Week 12…
